Remyelination in Multiple Sclerosis: Where Do We Stand?

In this initial episode, experts Ari Green, MD, and Paul Tesar, PhD, break down the biological foundation and therapeutic importance of remyelination in multiple sclerosis.

Neurologists Ari Green, MD, and Paul Tesar, PhD, discuss the current limitations of remyelination assessment tools in MS and highlight efforts to develop more reliable clinical measures.

In this episode, panelists outline the key scientific and clinical challenges in translating remyelination research into effective therapies for patients with MS.

Episode 4 covers how aging and disease duration impact remyelination potential and the strategies for targeting repair across the multiple sclerosis spectrum.

Panelists Ari Green, MD, and Paul Tesar, PhD, explore the scientific rationale and clinical complexity behind promising remyelination agents currently in development for multiple sclerosis.

In this episode, a duo of neurologists examine the plausibility, limitations, and risks of holistic approaches to remyelination—and what patients should prioritize or avoid.

The pair of neurologists highlight key advances needed in imaging, trial design, and preclinical modeling to drive remyelination breakthroughs in MS.